ASH 2023 | Second-generation FLT3 inhibitors in the treatment of FLT3-ITD AML
Musa Yilmaz
• 10 Dec 2023
Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores the use of second-generation FLT3 inhibitors, such as quizartinib, in treating patients with FLT3-ITD acute myeloid leukemia (AML). These inhibitors show efficacy as monotherapies and are undergoing trials in combination with hypomethylating agents plus venetoclax for older patients and intensive chemotherapy for younger patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Pfizer, Daiichi-Sankyo
